{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T20:20:39Z","timestamp":1767903639140,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,4,23]],"date-time":"2014-04-23T00:00:00Z","timestamp":1398211200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s10549-014-2968-9","type":"journal-article","created":{"date-parts":[[2014,4,22]],"date-time":"2014-04-22T12:57:14Z","timestamp":1398171434000},"page":"491-501","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy"],"prefix":"10.1007","volume":"145","author":[{"given":"Rachel A.","family":"Freedman","sequence":"first","affiliation":[]},{"given":"Ines","family":"Vaz-Luis","sequence":"additional","affiliation":[]},{"given":"William T.","family":"Barry","sequence":"additional","affiliation":[]},{"given":"Huichuan","family":"Lii","sequence":"additional","affiliation":[]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[]},{"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[]},{"given":"Nancy L.","family":"Keating","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2014,4,23]]},"reference":[{"key":"2968_CR1","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature01392","volume":"421","author":"HS Cho","year":"2003","unstructured":"Cho HS, Mason K, Ramyar KX et al (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756\u2013760","journal-title":"Nature"},{"issue":"Suppl 4","key":"2968_CR2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0959-8049(01)00230-1","volume":"37","author":"Y Yarden","year":"2001","unstructured":"Yarden Y (2001) The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 37(Suppl 4):S3\u2013S8","journal-title":"Eur J Cancer"},{"key":"2968_CR3","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1093\/jnci\/djs264","volume":"104","author":"CA Clarke","year":"2012","unstructured":"Clarke CA, Keegan TH, Yang J et al (2012) Age-specific incidence of breast cancer subtypes: understanding the black\u2013white crossover. J Natl Cancer Inst 104:1094\u20131101","journal-title":"J Natl Cancer Inst"},{"key":"2968_CR4","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jgo.2013.05.007","volume":"4","author":"H Laird-Fick","year":"2013","unstructured":"Laird-Fick H, Gardiner J, Tokala H et al (2013) HER2 status in elderly women with breast cancer. J Geriatr Oncol 4:362\u2013367","journal-title":"J Geriatr Oncol"},{"key":"2968_CR5","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684","journal-title":"N Engl J Med"},{"key":"2968_CR6","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672","journal-title":"N Engl J Med"},{"key":"2968_CR7","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","volume":"29","author":"EA Perez","year":"2011","unstructured":"Perez EA, Romond EH, Suman VJ et al (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366\u20133373","journal-title":"J Clin Oncol"},{"key":"2968_CR8","unstructured":"National Comprehensive Cancer Network (2013) Clinical practice guidelines in oncology. Breast Cancer V.3.2013 http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf . Accessed 10 Oct 2013"},{"key":"2968_CR9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/cncr.27831","volume":"119","author":"RA Freedman","year":"2013","unstructured":"Freedman RA, Hughes ME, Ottesen RA et al (2013) Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race\/ethnicity and education within the National Comprehensive Cancer Network. Cancer 119:839\u2013846","journal-title":"Cancer"},{"key":"2968_CR10","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2013.51.1261","volume":"32","author":"I Vaz-Luis","year":"2014","unstructured":"Vaz-Luis I, Keating NL, Lin NU et al (2014) Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol 32:927\u2013934","journal-title":"J Clin Oncol"},{"key":"2968_CR11","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2006.10.2749","volume":"25","author":"JJ Griggs","year":"2007","unstructured":"Griggs JJ, Culakova E, Sorbero ME et al (2007) Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol 25:2522\u20132527","journal-title":"J Clin Oncol"},{"key":"2968_CR12","unstructured":"Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds) SEER cancer statistics review, 1975\u20132008, National Cancer Institute, Bethesda. http:\/\/seer.cancer.gov\/csr\/1975_2008\/ , based on November 2010 SEER data submission, posted to the SEER web site, 2011"},{"key":"2968_CR13","unstructured":"SEER-Medicare: how the SEER & Medicare data are linked. http:\/\/healthservices.cancer.gov\/seermedicare\/overview\/linked.html . Accessed 20 Oct 2009"},{"key":"2968_CR14","first-page":"IV-3","volume":"40","author":"JL Warren","year":"2002","unstructured":"Warren JL, Klabunde CN, Schrag D et al (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40:IV-3\u2013IV-18","journal-title":"Med Care"},{"key":"2968_CR15","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/jnci\/djj305","volume":"98","author":"MJ Hassett","year":"2006","unstructured":"Hassett MJ, O\u2019Malley AJ, Pakes JR et al (2006) Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1108\u20131117","journal-title":"J Natl Cancer Inst"},{"key":"2968_CR16","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1200\/JCO.2002.05.088","volume":"20","author":"XL Du","year":"2002","unstructured":"Du XL, Osborne C, Goodwin JS (2002) Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 20:4636\u20134642","journal-title":"J Clin Oncol"},{"key":"2968_CR17","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","volume":"53","author":"CN Klabunde","year":"2000","unstructured":"Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258\u20131267","journal-title":"J Clin Epidemiol"},{"key":"2968_CR18","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245\u20131251","journal-title":"J Clin Epidemiol"},{"key":"2968_CR19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1020371312283","volume":"2","author":"K Hirano","year":"2001","unstructured":"Hirano K, Imbens G (2001) Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization. Health Serv Outcomes Res Method 2:259\u2013278","journal-title":"Health Serv Outcomes Res Method"},{"key":"2968_CR20","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/01621459.1984.10478078","volume":"79","author":"P Rosenbaum","year":"1984","unstructured":"Rosenbaum P, Rubin D (1984) Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 79:516\u2013524","journal-title":"J Am Stat Assoc"},{"key":"2968_CR21","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7326\/0003-4819-127-8_Part_2-199710151-00064","volume":"127","author":"DB Rubin","year":"1997","unstructured":"Rubin DB (1997) Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127:757\u2013763","journal-title":"Ann Intern Med"},{"key":"2968_CR22","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1198\/000313004X5824","volume":"58","author":"MM Joffe","year":"2004","unstructured":"Joffe MM, Ten Have TR, Feldman HI, Kimmel SE (2004) Model selection, confounder control, and marginal structural models: review and new applications. Am Statistician 58:272\u2013279","journal-title":"Am Statistician"},{"key":"2968_CR23","doi-asserted-by":"crossref","first-page":"948","DOI":"10.2307\/2533848","volume":"54","author":"DY Lin","year":"1998","unstructured":"Lin DY, Psaty BM, Kronmal RA (1998) Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 54:948\u2013963","journal-title":"Biometrics"},{"key":"2968_CR24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1200\/JCO.2008.21.3652","volume":"28","author":"EB Lamont","year":"2010","unstructured":"Lamont EB, Landrum MB, Keating NL et al (2010) Differences in clinical trial patient attributes and outcomes according to enrollment setting. J Clin Oncol 28:215\u2013221","journal-title":"J Clin Oncol"},{"key":"2968_CR25","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/jnci\/djg035","volume":"95","author":"EB Lamont","year":"2003","unstructured":"Lamont EB, Hayreh D, Pickett KE et al (2003) Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst 95:1370\u20131375","journal-title":"J Natl Cancer Inst"},{"key":"2968_CR26","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.293.9.1073","volume":"293","author":"HB Muss","year":"2005","unstructured":"Muss HB, Woolf S, Berry D et al (2005) Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073\u20131081","journal-title":"JAMA"},{"key":"2968_CR27","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1200\/JCO.2007.10.9710","volume":"25","author":"HB Muss","year":"2007","unstructured":"Muss HB, Berry DA, Cirrincione C et al (2007) Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the cancer and leukemia group B experience. J Clin Oncol 25:3699\u20133704","journal-title":"J Clin Oncol"},{"key":"2968_CR28","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1200\/JCO.2003.02.046","volume":"21","author":"C Bouchardy","year":"2003","unstructured":"Bouchardy C, Rapiti E, Fioretta G et al (2003) Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 21:3580\u20133587","journal-title":"J Clin Oncol"},{"key":"2968_CR29","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1104::AID-CNCR14>3.0.CO;2-1","volume":"85","author":"N Hebert-Croteau","year":"1999","unstructured":"Hebert-Croteau N, Brisson J, Latreille J et al (1999) Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women. Cancer 85:1104\u20131113","journal-title":"Cancer"},{"key":"2968_CR30","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1200\/JCO.2005.03.6053","volume":"24","author":"EB Elkin","year":"2006","unstructured":"Elkin EB, Hurria A, Mitra N et al (2006) Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol 24:2757\u20132764","journal-title":"J Clin Oncol"},{"key":"2968_CR31","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1200\/JCO.2005.02.3028","volume":"24","author":"SH Giordano","year":"2006","unstructured":"Giordano SH, Duan Z, Kuo YF et al (2006) Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24:2750\u20132756","journal-title":"J Clin Oncol"},{"key":"2968_CR32","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jama.285.7.885","volume":"285","author":"R Yancik","year":"2001","unstructured":"Yancik R, Wesley MN, Ries LA et al (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55\u00a0years and older. JAMA 285:885\u2013892","journal-title":"JAMA"},{"key":"2968_CR33","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2003.12.109","volume":"21","author":"B Leyland-Jones","year":"2003","unstructured":"Leyland-Jones B, Gelmon K, Ayoub JP et al (2003) Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21:3965\u20133971","journal-title":"J Clin Oncol"},{"key":"2968_CR34","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783\u2013792","journal-title":"N Engl J Med"},{"key":"2968_CR35","doi-asserted-by":"crossref","unstructured":"Tolaney SM, Barry WT, Dang CT et al (2013) A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT Trial) for node-negative, HER2-positive breast cancer (BC). Presented at the San Antonio Breast Cancer Symposium on 12 Dec 2013, Abstract #974","DOI":"10.1158\/0008-5472.SABCS13-S1-04"},{"key":"2968_CR36","first-page":"55","volume":"40","author":"JL Warren","year":"2002","unstructured":"Warren JL, Harlan LC, Fahey A et al (2002) Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 40:55\u201361","journal-title":"Med Care"},{"key":"2968_CR37","doi-asserted-by":"crossref","unstructured":"Bikov KA, Mullins CD, Seal B et al (2013) Algorithm for identifying chemotherapy\/biological regimens for metastatic colon cancer in SEER-Medicare. Med Care. epub ahead of print","DOI":"10.1097\/MLR.0b013e31828fad9f"},{"key":"2968_CR38","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1097\/MLR.0b013e31823ab60f","volume":"51","author":"JL Lund","year":"2013","unstructured":"Lund JL, Sturmer T, Harlan LC et al (2013) Identifying specific chemotherapeutic agents in Medicare data: a validation study. Med Care 51:e27\u2013e34","journal-title":"Med Care"},{"key":"2968_CR39","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1200\/JCO.2012.42.0695","volume":"30","author":"HJ Burstein","year":"2012","unstructured":"Burstein HJ, Piccart-Gebhart MJ, Perez EA et al (2012) Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol 30:2179\u20132182","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-2968-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-014-2968-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-2968-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T16:05:10Z","timestamp":1565366710000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-014-2968-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,23]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["2968"],"URL":"https:\/\/doi.org\/10.1007\/s10549-014-2968-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,23]]}}}